Oncology

Resource Center

Videos

Treatment of Cancer

Must All Cancer Treatments Have Adverse Effects?

09/22/2016

Craig A. Dionne, PhD, CEO of GenSpera, describes some of the drawbacks associated with common cancer treatments. Many types of drug therapies, like antiangiogenics and immunotherapies, may only be effective...

09/22/2016

Research Summaries

FDA Alert

FDA Alert

FDA Approves Relacorilant (Lifyorli) Plus Nab-Paclitaxel for Platinum-Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

04/23/2026

Anthony Calabro, MA

On March 25, the FDA has approved relacorilant (Lifyorli), in combination with nab-paclitaxel for adults with platinum-resistant ovarian and related gynecologic cancers who have received prior systemic...

04/23/2026

Research Summary

Breast cancer physician and patient image

Research Summary

Study: HRT After Oophorectomy Did Not Raise Breast Cancer Risk in BRCA Carriers

04/20/2026

Ashton L. Stahl

In a multicenter cohort, post-oophorectomy HRT was not linked to higher breast cancer risk in women with BRCA variants.

04/20/2026

FDA Approval

FDA Approval

Tecartus (brexucabtagene autoleucel) Receives FDA Approval for Relapsed or Refractory Mantle Cell Lymphoma

04/15/2026

Anthony Calabro, MA

The FDA has granted full approval for the use of brexucabtagene autoleucel in adults with relapsed or refractory mantle cell lymphoma, based on confirmatory ZUMA-2 data.

04/15/2026

Research Summary

Research Summary

Optimizing Cervical Cancer Screening by Age at HPV Vaccination in Norway: Modeling Study Suggests Less Frequent Screening

03/26/2026

Ashton L. Stahl

As HPV-vaccinated cohorts age into screening eligibility, researchers evaluated how cervical cancer screening intensity could be tailored by age at vaccination and vaccine type to balance benefits, harms,...

03/26/2026

FDA Alert

FDA Alert

FDA Approves Opdivo Plus AVD for Previously Untreated Stage III/IV Classical Hodgkin Lymphoma

03/24/2026

Ashton L. Stahl

The FDA has approved Opdivo (nivolumab) in combination with doxorubicin, vinblastine, and dacarbazine for adults and pediatric patients aged 12 years and older with previously untreated stage III or IV...

03/24/2026

April 2026

Current Issue

April 2026